



[www.MedChemExpress.com](http://www.MedChemExpress.com)

Inhibitors, Screening Libraries, Proteins











# Xanthine Oxidase











XO










Xanthine oxidase (XO), a versatile molybdoflavoprotein, catalyzes the oxidative hydroxylation of purine substrates (hypoxanthine and xanthine) to produce uric acid and subsequent reduction of oxygen at the flavin center with the generation of reactive oxygen species, either superoxide anion radical or hydrogen peroxide.

Xanthine oxidase is an important enzyme of purine catabolism pathway and has been associated directly in pathogenesis of gout and indirectly in many pathological conditions like cancer, diabetes and metabolic syndrome. The selective inhibition of xanthine oxidase may result in a broad spectrum therapeutic use for gout, cancer, inflammation and oxidative damage.

## Xanthine Oxidase Inhibitors

<p><b>Allopurinol</b></p> <p>Cat. No.: HY-B0219</p> <p>Allopurinol is a potent <b>xanthine oxidase</b> inhibitor (<math>IC_{50}</math> values of 0.2 to 50 <math>\mu</math>M). Allopurinol can be used for the research of hyperuricemia and gout. Antileishmanial effect.</p> <p><b>Purity:</b> 99.92%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 5 g, 10 g</p> 	<p><b>Allopurinol sodium</b></p> <p>Cat. No.: HY-B0219A</p> <p>Allopurinol sodium is a potent <b>xanthine oxidase</b> inhibitor (<math>IC_{50}</math> values of 0.2 to 50 <math>\mu</math>M). Allopurinol sodium can be used for the research of hyperuricemia and gout. Antileishmanial effect.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>Allopurinol-d2</b></p> <p>Cat. No.: HY-B0219S</p> <p>Allopurinol-d2 is deuterium labeled Allopurinol. Allopurinol is a potent xanthine oxidase inhibitor (<math>IC_{50}</math> values of 0.2 to 50 <math>\mu</math>M). Allopurinol can be used for the research of hyperuricemia and gout. Antileishmanial effect.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Baicalein</b> (5,6,7-Trihydroxyflavone)</p> <p>Cat. No.: HY-N0196</p> <p>Baicalein (5,6,7-Trihydroxyflavone) is a <b>xanthine oxidase</b> inhibitor with an <math>IC_{50}</math> value of 3.12 <math>\mu</math>M.</p> <p><b>Purity:</b> 99.13%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p> 
<p><b>Benzbromarone</b></p> <p>Cat. No.: HY-B1135</p> <p>Benzbromarone is a highly effective and well tolerated non-competitive inhibitor of xanthine oxidase, used as an uricosuric agent, used in the treatment of gout.</p> <p><b>Purity:</b> 99.80%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p> 	<p><b>Benzbromarone-d5</b></p> <p>Cat. No.: HY-B1135S</p> <p>Benzbromarone-d5 is deuterium labeled Benzbromarone.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>Broussoflavonol F</b></p> <p>Cat. No.: HY-N9330</p> <p>Broussoflavonol F possess <b>xanthine oxidase</b> inhibitory activity.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg</p> 	<p><b>Febuxostat</b> (TEI 6720; TMX 67)</p> <p>Cat. No.: HY-14268</p> <p>Febuxostat (TEI 6720) is selective <b>xanthine oxidase</b> inhibitor with a <math>K_i</math> of 0.6 nM.</p> <p><b>Purity:</b> 99.90%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p> 
<p><b>Febuxostat D9</b></p> <p>Cat. No.: HY-14268S</p> <p>Febuxostat D9 is deuterium labeled Febuxostat, which is a selective xanthine oxidase inhibitor with a <math>K_i</math> of 0.6 nM.</p> <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Febuxostat-d7</b> (TEI 6720-d7; TMX 67-d7)</p> <p>Cat. No.: HY-14268S1</p> <p>Febuxostat-d7 is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is selective xanthine oxidase inhibitor with a <math>K_i</math> of 0.6 nM.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 

<p><b>Forsythoside F</b> (Arenarioside)</p> <p>Forsythoside F (Arenarioside) is a <b>xanthine oxidase</b> inhibitor and possesses antihyperuricemic effects in vivo.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg</p>	<p><b>Cat. No.:</b> HY-N7397</p>  <p><b>Ilexoside O</b></p> <p>Ilexoside O is a triterpene saponin isolated from the roots of <i>Ilex pubescens</i>. Ilexoside O exhibits weak <b>xanthine oxidase (XOD)</b> inhibitory activity (<math>IC_{50}</math>=53.05 <math>\mu</math>M).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg</p>	<p><b>Cat. No.:</b> HY-N9324</p> 
<p><b>Lobetyolin</b></p> <p>Lobetyolin, a bioactive compound, is derived from <i>Codonopsis pilosula</i>. Lobetyolin has anti-inflammatory, anti-oxidative and <b>xanthine oxidase</b> inhibiting activities. Lobetyolin also induces the apoptosis via the inhibition of ASCT2-mediated glutamine metabolism.</p> <p><b>Purity:</b> 99.89% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg</p>	<p><b>Cat. No.:</b> HY-N0327</p>  <p><b>Myricetin 3-O-galactoside</b></p> <p>Myricetin 3-O-galactoside inhibits <b>xanthine oxidase (XO)</b> activity, lipid peroxidation and scavenges the free radical. Myricetin 3-O-galactoside inhibits lipid peroxidation with an <math>IC_{50}</math> of 160 <math>\mu</math>g/mL. Antioxidant activity.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg</p>	<p><b>Cat. No.:</b> HY-N3220</p> 
<p><b>Nequinat</b></p> <p>Nequinat, a quinoline compound, is an anticoccidial agent against cecal coccidiosis (<i>Eimeria tenella</i>) infections. Nequinat inhibits xanthine oxidoreductase (<b>XOD</b>) activity.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Cat. No.:</b> HY-116433</p>  <p><b>O-Desisobutyl-O-n-propyl Febuxostat</b></p> <p>O-Desisobutyl-O-n-propyl Febuxostat, extracted from the patent CN 103467412, is a <b>xanthine oxidase</b> inhibitor.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-131268</p> 
<p><b>Oxipurinol</b> (Oxipurinol)</p> <p>Oxipurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of <b>xanthine oxidase</b>. Oxipurinol can be used to regulate blood urate levels and treat gout.</p> <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> Phase 3 <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg</p>	<p><b>Cat. No.:</b> HY-19657</p>  <p><b>Phytic acid (Inositol hexaphosphate; myo-Inositol, hexakis(dihydrogen phosphate))</b></p> <p>Phytic acid is a phosphorus storage compound of seeds and cereal grains. Phytic acid is known as a food inhibitor, which has a strong ability to chelate multivalent metal ions, specially zinc, calcium, iron and as with protein residue.</p> <p><b>Purity:</b> <math>\geq</math>95.0% <b>Clinical Data:</b> Launched <b>Size:</b> 250 mg (757.5 mM * 500 <math>\mu</math>L in Water) ,</p>	<p><b>Cat. No.:</b> HY-N0814</p> 
<p><b>Phytic acid dodecasodium salt hydrate (Inositol hexaphosphate dodecasodium salt hydrate; ...)</b></p> <p>Phytic acid dodecasodium salt hydrate is a phosphorus storage compound of seeds and cereal grains.</p> <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> Phase 3 <b>Size:</b> 250 mg</p>	<p><b>Cat. No.:</b> HY-N0814A</p>  <p><b>Prudomestin</b></p> <p>Prudomestin, isolated from the heartwood of <i>Prunus domestica</i>, shows potent <b>xanthine oxidase (XO)</b> inhibitory activity (<math>IC_{50}</math><math>\approx</math>6 <math>\mu</math>M).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>	<p><b>Cat. No.:</b> HY-N1547</p> 

<p><b>Purpurogallin</b></p> <p style="text-align: right;">Cat. No.: HY-12136</p>	<p><b>Tigulixostat</b> (LC350189)</p> <p style="text-align: right;">Cat. No.: HY-139585</p>
<p>Purpurogallin is a naturally phenol extracted from the plants of <i>Quercus</i> spp, has potent <b>xanthine oxidase (XO)</b> inhibitory activity with an <math>IC_{50}</math> of 0.2 <math>\mu</math>M. Purpurogallin has antioxidant and anti-inflammatory effects.</p> <p style="text-align: center;"></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Tigulixostat (LC350189) is an orally active, non-purine selective <b>xanthine oxidase</b> inhibitor. Tigulixostat lowers the production of uric acid. Tigulixostat can be used for gout and hyperuricemia study.</p> <p style="text-align: center;"></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Topiroxostat</b> (FYX-051)</p> <p style="text-align: right;">Cat. No.: HY-14874</p>	<p><b>Topiroxostat-d4</b> (FYX-051-d4)</p> <p style="text-align: right;">Cat. No.: HY-14874S</p>
<p>Topiroxostat (FYX-051) is a potent and orally active <b>xanthine oxidoreductase (XOR)</b> inhibitor with an <math>IC_{50}</math> value of 5.3 nM and a <math>K_i</math> value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment.</p> <p style="text-align: center;"></p> <p><b>Purity:</b> 99.68% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Topiroxostat-d4 is deuterium labeled Topiroxostat. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an <math>IC_{50}</math> value of 5.3 nM and a <math>K_i</math> value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%).</p> <p style="text-align: center;"></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Xanthine oxidase-IN-1</b> (4-(3-Cyano-5,6-difluorindol-1-yl)-2-hydroxybenzoic acid) Cat. No.: HY-U00288</p>	<p><b>Xanthine oxidase-IN-4</b></p> <p style="text-align: right;">Cat. No.: HY-144303</p>
<p>Xanthine oxidase-IN-1 is a <b>xanthine oxidase</b> inhibitor extracted from patent WO2008126898A1, page 68, compound example 3, with an <math>IC_{50}</math> of 6.5 nM.</p> <p style="text-align: center;"></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent <b>xanthine oxidase (XO)</b> inhibitor, with an <math>IC_{50}</math> of 0.039 <math>\mu</math>M. Xanthine oxidase-IN-4 exhibits hypouricemic potency in potassium oxonate induced hyperuricemia rats. Xanthine oxidase-IN-4 can be used for hyperuricemia and gout research.</p> <p style="text-align: center;"></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Xanthine oxidase-IN-5</b></p> <p style="text-align: right;">Cat. No.: HY-144456</p>	<p><b>Xanthine oxidase-IN-6</b></p> <p style="text-align: right;">Cat. No.: HY-146560</p>
<p>Xanthine oxidase-IN-5 is an effective and orally active <b>xanthine oxidase (XO)</b> inhibitor with <math>IC_{50}</math> value of 0.70 <math>\mu</math>M.</p> <p style="text-align: center;"></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Xanthine oxidase-IN-6 (Compound 6c) is a potent, orally active, mixed-type xanthine oxidase (XOD) inhibitor with an <math>IC_{50}</math> value of 1.37 <math>\mu</math>M. Xanthine oxidase-IN-6 shows strong <b>anti-hyperuricemia</b> and renal protective activity.</p> <p style="text-align: center;"></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Xanthine oxidase-IN-7</b></p> <p style="text-align: right;">Cat. No.: HY-146273</p>	
<p>Xanthine oxidase-IN-7 (compound1h) is a potent andorally active <b>XO (xanthine oxidase)</b> inhibitor with an <math>IC_{50}</math> of 0.36 <math>\mu</math>M. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout.</p> <p style="text-align: center;"></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	